Every Ozempic Alternative Compared
Ozempic alternatives range from FDA-approved injections and pills to investigational compounds. In their landmark trials, semaglutide 2.4 mg (Wegovy) averaged 14.9% weight loss at 68 weeks (STEP 1, PMID: 33567185) and tirzepatide (Zepbound) 20.9% at the 15 mg dose over 72 weeks (SURMOUNT-1, PMID: 35658024); investigational retatrutide reached 25.0% at 12 mg over 80 weeks in its Phase 3 TRIUMPH-1 trial (PMID: 42814954), up from 24.2% at 48 weeks in Phase 2. This comparison covers efficacy, cost, availability, regulatory status, and side effects.
(Phase 3 TRIUMPH-1, 80wk)
(SURMOUNT-1, 15 mg, 72wk)
(STEP 1, 68wk)
Still logging injections in your Notes app?
A notes thread can't show a missed day at a glance, because it's a list, not a calendar. A printed log can. Your compounds and dates filled in: injection log, weekly schedule, dated calendar. Free to build and preview; $5/month to unlock printing.
The Problem
Why People Look for Ozempic Alternatives
Ozempic and Wegovy changed weight loss forever, but they're not perfect for everyone. Here's why millions of people are searching for alternatives.
Prohibitive Cost
Many plans don't cover weight loss medications. Manufacturer self-pay programs have cut cash prices — Wegovy pens list at $349/month via NovoCare and Zepbound starts at $299/month via Lilly — but that is still a real monthly bill.
Side Effects
GI side effects are common: nausea hit 44% of Wegovy 2.4 mg patients and 25–29% of Zepbound patients in label trials (vs 16% and 8% on placebo) — see the Wegovy and Zepbound labels. Some people who struggle with one drug look for another.
Shortage-Era Options Ended
FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025 — ending the grace periods that let compounders sell copies. People who relied on those copies need another route.
Better Options Exist
In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss vs 13.7% with semaglutide at 72 weeks (PMID: 40353578). Next-gen compounds in trials show even greater efficacy.
Available Now
FDA-Approved GLP-1 Alternatives
These drugs are currently available by prescription. Tirzepatide is the standout: it beat semaglutide head-to-head in SURMOUNT-5.
Coming Soon
Investigational & Emerging Compounds
The next generation of weight loss drugs. Most aren't available yet (orforglipron was approved in April 2026), but they show where the field is heading.
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. In the Phase 3 TRIUMPH-1 trial, adults with obesity lost an average of 25.0% of body weight at 12 mg over 80 weeks vs 3.9% on placebo, using the treatment-regimen estimand (PMID: 42814954). In TRIUMPH-2, adults with obesity and type 2 diabetes lost 18.8% vs 5.1% (PMID: 42810372). Phase 2 had shown 24.2% at 48 weeks (PMID: 37366315). It is not FDA-approved.
A dual GLP-1/glucagon agonist (different dual combo than tirzepatide). Its Phase 3 trials (NEJM 2026) showed 13.0% average weight loss at 6.0mg/76 weeks vs 5.4% on placebo in adults without type 2 diabetes (SYNCHRONIZE-1, PMID: 42253238), and 9.8% vs 3.9% in adults with type 2 diabetes (SYNCHRONIZE-2, PMID: 42820639), using the treatment-regimen estimand. Phase 2 had shown 14.9% at 4.8mg/46 weeks (Lancet Diabetes Endocrinol 2024, PMID: 38330987). Also being studied for MASH/NAFLD (fatty liver disease).
A non-peptide oral GLP-1 agonist: a daily pill that can be taken any time of day without food or water restrictions. FDA approved it as Foundayo on April 1, 2026; Lilly lists self-pay pricing from $149/month. In Phase 3 ATTAIN-1, the 36 mg dose produced 11.2% average weight loss at 72 weeks vs 2.1% on placebo (PMID: 40960239); Phase 2 had shown up to 14.7% at 36 weeks (PMID: 37351564).
Novo Nordisk's answer to the oral GLP-1 challenge. Amycretin (now named zenagamtide) is a dual amylin/GLP-1 agonist developed as both a pill and an injection. Novo reported 13.1% weight loss after 12 weeks in a Phase 1 study of the oral version (company-reported) and says Phase 3 for weight management got underway in early 2026 (Novo Nordisk). Still early stage.
Regulatory Status
Compounded Semaglutide
Compounded semaglutide boomed during the national shortage. That shortage is over, and so is the legal room for routine copies.
How It Works
While a drug is on FDA's shortage list, compounders may make copies of it. Once a shortage is resolved, FDA generally considers the drug commercially available, and compounding copies is allowed only if it is not done "regularly or in inordinate amounts." FDA declared the semaglutide injection shortage resolved on February 21, 2025 (tirzepatide: December 19, 2024).
Compounded semaglutide is made by compounding pharmacies rather than Novo Nordisk, and compounded drugs are not FDA-approved: FDA does not review them for safety, effectiveness or quality before they are marketed.
Grace Periods Ended in 2025
After the shortage ended, FDA gave compounders a transition window: enforcement discretion for semaglutide ended in late April 2025 for 503A pharmacies (after an April 24, 2025 court ruling) and on May 22, 2025 for 503B outsourcing facilities. Those dates have passed. If you want semaglutide at a lower cash price, the approved route is the manufacturer's self-pay program — NovoCare lists Wegovy pens at $349/month and the Wegovy pill from $149/month.
shortage resolved
(monthly, pill or pen, NovoCare)
Important Considerations
Compounded semaglutide is not an FDA-approved product, and with the shortage resolved, compounders can no longer routinely make copies of the approved drug. Treat any "semaglutide" offered outside a licensed pharmacy filling an approved product with caution, and discuss options with your prescriber.
Not Always the Same Molecule
FDA has warned that some compounders sell semaglutide sodium or semaglutide acetate. These salt forms are different active ingredients from the one in Ozempic and Wegovy, and FDA says it lacks information on whether they behave the same way.
No Prescription Required
Natural & OTC Alternatives
Supplements, lifestyle changes, and non-prescription approaches. We'll be honest: none of these come close to prescription GLP-1 drugs, but they have their place.
Side-by-Side
Decision Matrix: Every Option Compared
All alternatives in one view. Scroll horizontally on mobile. Sort by what matters most to you: efficacy, cost, or availability.
| Drug / Option | Mechanism | Efficacy | Monthly Cost | Route | Availability | Key Side Effects |
|---|---|---|---|---|---|---|
| Tirzepatide Zepbound |
Dual GIP + GLP-1 | 20.9% | From $299 self-pay | Weekly injection | Available now | Nausea, diarrhea, constipation |
| Semaglutide Wegovy/Ozempic |
GLP-1 only | 14.9% | $349 self-pay (Wegovy pen) | Weekly injection | Available now | Nausea, vomiting, diarrhea |
| Liraglutide Saxenda |
GLP-1 only (older) | 7.4% | Generic; varies | Daily injection | Available now | Nausea, headache, hypoglycemia |
| Wegovy pill Oral semaglutide 25 mg |
GLP-1 (oral) | 13.6% | $149–299 self-pay | Daily pill | Approved (Dec 2025) | Nausea, vomiting, diarrhea |
| Retatrutide Triple agonist |
GIP + GLP-1 + GCG | 25.0% | TBD | Weekly injection | Investigational (Phase 3) | Nausea, diarrhea, vomiting; hypotension, dysesthesia |
| Survodutide | GLP-1 + Glucagon | 13.0% | TBD | Weekly injection | Phase 3 reported (2026) | GI effects |
| Orforglipron | Non-peptide GLP-1 (oral) | 11.2% | From $149 self-pay | Daily pill | Approved (Apr 2026) | Nausea, vomiting, diarrhea |
| Amycretin | Amylin + GLP-1 (oral) | 13.1%* | TBD | Daily pill | Phase 3 | GI effects (early data) |
| Compounded Semaglutide | GLP-1 only | Not FDA-reviewed | — | Weekly injection | Shortage over (Feb 2025); copies no longer routine | Quality not FDA-reviewed; some use salt forms |
| Berberine | AMPK activator | ~0.9 kg vs control | $15–30 | Oral supplement | OTC | GI discomfort, drug interactions |
| Diet + Exercise | Lifestyle | Modest; varies | Free | N/A | Always available | Requires sustained effort |
* Amycretin 13.1% was at 12 weeks in a Phase 1 study (company-reported); longer-term data pending. Other drug figures are at study endpoint (56–80 weeks); self-pay prices are manufacturer-listed as of October 2026 and change often.
Safety Profile
Side Effects Across GLP-1 Drugs
Most GLP-1 drugs share similar side effects because they work through related pathways. Ranges below span the FDA labels for Zepbound 5–15 mg and Wegovy 2.4 mg injection (placebo-controlled weight-loss trials); bars show the higher figure. Sources: Zepbound label, Wegovy label.
Titration Reduces Side Effects
Both labels start at a low dose and step up gradually to reduce the risk of GI side effects; if a dose isn't tolerated, the Wegovy label suggests delaying the next increase. In the SURMOUNT-5 trial, GI events were mostly mild to moderate and occurred primarily during dose escalation (PMID: 40353578).
Rare but Serious Risks
The Wegovy and Zepbound labels carry a boxed warning for thyroid C-cell tumors (seen in rodents; human relevance not determined). Acute pancreatitis and acute gallbladder disease are listed under Warnings and Precautions. Always discuss personal risk factors with your physician.
Muscle Loss Mitigation
GLP-1 drugs cause weight loss from both fat and lean mass. Resistance training and adequate protein intake are commonly recommended to help preserve muscle during treatment.
Bottom Line
Choosing the Right Alternative
What matters most for different situations.
- Best efficacy (available now): Tirzepatide (Zepbound): 20.9% weight loss in SURMOUNT-1, and it beat semaglutide head-to-head in SURMOUNT-5
- Lowest cash price: Manufacturer self-pay programs — Wegovy pill and Foundayo from $149/month, Zepbound from $299/month. Generic liraglutide is also available (price varies by pharmacy). Compounded semaglutide is no longer a routine option since the 2025 shortage resolution.
- Hate injections: Wegovy pill (approved Dec 2025) or Foundayo/orforglipron (approved Apr 2026)
- Maximum weight loss (future): Retatrutide: 25.0% at 80 weeks in Phase 3 TRIUMPH-1; not yet FDA-approved
- Supplement stack: Berberine + fiber + protein + exercise: modest but real benefits, no prescription needed
- Individual response varies significantly: some people lose more on semaglutide than others do on tirzepatide
- Insurance coverage often dictates the "best" option more than clinical efficacy does
- GLP-1 drugs are meant for ongoing use: in withdrawal trials, much of the lost weight returned after stopping semaglutide (STEP 1 extension, PMID: 35441470) or switching from tirzepatide to placebo (SURMOUNT-4, PMID: 38078870)
- FDA declared the tirzepatide (Dec 2024) and semaglutide (Feb 2025) shortages resolved, so compounded copies are no longer a routine option
- Emerging drugs may look impressive in trials but haven't been tested in real-world populations at scale
Dive Deeper
Related HighPeptides Resources
Research breakdowns, calculators, and comparison tools for every GLP-1 drug mentioned above.
Recommended
Weight Loss Journey Essentials
Track your progress and support your protocol with these essentials.
Affiliate links support HighPeptides at no extra cost.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
⚕️ Medical Disclaimer: This page is for educational and informational purposes only. It is not medical advice and should not be used as a substitute for professional medical consultation. All medications discussed carry risks and require physician oversight. Never start, stop, or change medications without consulting a qualified healthcare provider. Weight loss results vary by individual. Data sourced from published peer-reviewed clinical trials (STEP, SURMOUNT, TRIUMPH, SCALE, OASIS, ATTAIN, SYNCHRONIZE), FDA drug labels and FDA compounding statements; prices are manufacturer-listed self-pay prices as of October 2026, and amycretin data are company-reported. Always verify current drug availability and pricing with your pharmacy or prescriber.
HighPeptides · Research Library · © 2026
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.